Literature DB >> 16402090

Watchful waiting for prostate cancer: a review article.

G W Chodak1, K S Warren.   

Abstract

As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literature searches for studies examining outcomes of watchful waiting and examined new literature emerging about the use of PSA for the follow-up of watchful waiting patients. Watchful waiting has the potential to play an increasingly important role in prostate cancer as less advanced disease is detected and methods are refined for identifying low-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402090     DOI: 10.1038/sj.pcan.4500857

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  7 in total

1.  Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.

Authors:  M Suzanne Stratton; Amit M Algotar; James Ranger-Moore; Steven P Stratton; Elizabeth H Slate; Chiu-Hsieh Hsu; Patricia A Thompson; Larry C Clark; Frederick R Ahmann
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-20

2.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

3.  Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.

Authors:  Jenny L Donovan
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 4.  Autophagy as a modulator and target in prostate cancer.

Authors:  Jason M Farrow; Joy C Yang; Christopher P Evans
Journal:  Nat Rev Urol       Date:  2014-08-19       Impact factor: 14.432

5.  Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.

Authors:  A M Algotar; P A Thompson; J Ranger-Moore; M S Stratton; C H Hsu; F R Ahmann; R B Nagle; S P Stratton
Journal:  Intern Med J       Date:  2012-04       Impact factor: 2.048

6.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Authors:  Jennifer A Sinnott; Sam F Peisch; Svitlana Tyekucheva; Travis Gerke; Rosina Lis; Jennifer R Rider; Michelangelo Fiorentino; Meir J Stampfer; Lorelei A Mucci; Massimo Loda; Kathryn L Penney
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

7.  Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.

Authors:  Yunee Kim; Vladimir Ignatchenko; Cindy Q Yao; Irina Kalatskaya; Julius O Nyalwidhe; Raymond S Lance; Anthony O Gramolini; Dean A Troyer; Lincoln D Stein; Paul C Boutros; Jeffrey A Medin; O John Semmes; Richard R Drake; Thomas Kislinger
Journal:  Mol Cell Proteomics       Date:  2012-09-17       Impact factor: 5.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.